pentadecapeptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-08-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
| Property | Value | Notes |
|---|---|---|
| Amino acid count | 15 residues | Synthetic pentadecapeptide chain |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Molecular formula | C62H98N16O22 | Free peptide, without counter-ion |
| Theoretical mass | Approximately 1419.5 daltons | Varies slightly with adducts and counter-ions |
| Origin | Fragment of a human gastric juice protein | Source of the BPC designation |
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
==== Bariatric surgery ==== Bariatric surgery may be indicated in cases of severe obesity. Two common bariatric surgical procedures are gastric bypass and gastric banding. Both can be effective at limiting the intake of food energy by reducing the size of the stomach, but as with any surgical procedure both come with their own risks that should be considered in consultation with a physician.
ATPases (EC 3.6.1.3, Adenosine 5'-TriPhosphatase, adenylpyrophosphatase, ATP monophosphatase, triphosphatase, ATP hydrolase, adenosine triphosphatase) are a class of enzymes that catalyze the decomposition of ATP into ADP and a free phosphate ion or the inverse reaction. This dephosphorylation reaction releases energy, which the enzyme (in most cases) harnesses to drive other chemical reactions that would not otherwise occur. This process is widely used in all known forms of life. Some such enzymes are integral membrane proteins (anchored within biological membranes), and move solutes across the membrane, typically against their concentration gradient. These are called transmembrane ATPases.
Charnia fossils were originally found in the Charnwood Forest in England, hence named Charnia. These fossils are from marine organisms that lived on the bottom of the ocean floor. The fossils have a fractal body plan and were frond shaped, meaning they resembled broad-leafed plants such as ferns. However they could not have been plants since they resided in the dark depths of the ocean floor. In Charnwood Forest, Charnia was found as an isolated species, however there were many more fossils found on the East Coast of Canada in Mistaken Point in Newfoundland. Charnia was attached to the bottom of the ocean floor, and was strongly current aligned. This is seen because there are disk-like shapes at the bottom of the Charnia fossil, which show where Charnia was tethered, and all the nearby fossils are facing the same direction. These fossils at Mistaken Point were preserved well under volcanic ash and layers of soft mud. It has been determined via radiometric dating of the fossils that Charnia must have lived around 565 million years ago.
== Discovery == R7 was synthesized by the same researchers who were involved in the discovery of tropoflavin. A patent was filed for R7 in 2013 and was published in 2015. In 2016, it was reported to be in the preclinical stage of development. R7 was superseded by R13 because while R7 had a good drug profile in animals, it showed almost no conversion into tropoflavin in human liver microsomes. Tropoflavin, a naturally occurring flavonoid, was found to act as an agonist of the TrkB with nanomolar affinity (Kd ≈ 320 nM). Due to the presence of a vulnerable catechol group on its 2-phenyl-4H-chromene ring, tropoflavin is extensively conjugated via glucuronidation, sulfation, and methylation during first-pass metabolism in the liver and has a poor oral bioavailability of only 5% in mice upon oral administration. As such, tropoflavin itself is a poor candidate for clinical development as an oral medication. R7 is a derivative of tropoflavin with carbamate moieties on its hydroxyl groups, thereby protecting it from metabolism.
=== Venture capital === Verdine has worked in the venture capital industry as a Venture Partner with Apple Tree Partners, Third Rock Ventures, and WuXi Healthcare Ventures, and as a Special Advisor to Texas Pacific Group.
Sources: en.wikipedia.org
Just behind Piazza Castello stands the Turin Cathedral, dedicated to Saint John the Baptist, which is the major church of the city. It was built during 1491–1498 and is adjacent to an earlier bell tower (1470). Annexed to the cathedral is the Chapel of the Holy Shroud, the current resting place of the Shroud of Turin. The chapel was added to the structure in 1668–1694, designed by Guarini. The Basilica of Corpus Domini was built to celebrate an alleged miracle which took place during the sack of the city in 1453, when a soldier was carrying off a monstrance containing the Blessed Sacrament; the monstrance fell to the ground, while the host remained suspended in air. The present church, erected in 1610 to replace the original chapel which stood on the spot, is the work of Ascanio Vitozzi.
The vertical bars ("|") in the above list are not separators in the sense of the Backus–Naur form but are part of the format. Multiple identifiers can be concatenated, also separated by vertical bars.
=== Marketing === Il-86 provision to Aeroflot did not constitute a sale: it was part of the centralised Soviet supply and allocation system coordinated by offices called Gosplan and Gossnab which controlled the entirety of planning and distribution in the USSR (except the black market). Built aircraft were allocated to Aeroflot regions and Soviet Air Force units as follows (in order of first acceptance): the Vnukovo Aviation Enterprise, 21 aircraft; the TsUMVS Administration of International Air Communications centred on Sheremetyevo Airport, 22; the Tashkent Air Enterprise, 9; the Sheremetyevo Air Enterprise, 10; the Pulkovo Air Enterprise, 8; the Alma-Ata Air Enterprise, 8; the Chkalovsky Soviet Air Force Base 8 ADON (or 8th Special Purposes Aviation Division), 4; the Kol'tsovo Air Enterprise, 6; the Tolmachevo Air Enterprise, 6; the Erevan Air Enterprise, 2; the Yemelyanovo Air Enterprise, 3. Selling the Il-86 commercially (which under the Soviet system meant solely exports) was the job of the Soviet foreign trade organisation V/O Aviaeksport. The division of responsibilities between the influential TsAGI research establishment, design bureaux (acting like naval architects) which designed aeroplanes, factories (independent of the bureaux) which constructed them, independent service facilities which repaired them and an independent organisation which marketed them alongside designs by all other bureaux, has been seen as diluting responsibility for the fate of a product.
=== OSMI === OSMI-1 was first identified from high-throughput screening using fluorescence polarization. Further optimization led to the development of OSMI-2, OSMI-3, and OSMI-4, which bind OGT with low-nanomolar affinity. X-ray crystallography showed that the quinolinone-6-sulfonamide scaffold of OSMI compounds act as a uridine mimetic. OSMI-2, OSMI-3, and OSMI-4 have negatively charged carboxylate groups; esterification renders these inhibitors cell-permeable.
==== Extraction ==== Extraction of polyphenols can be performed using a solvent like water, hot water, methanol, methanol/formic acid, methanol/water/acetic or formic acid. Liquid–liquid extraction can be also performed or countercurrent chromatography. Solid phase extraction can also be made on C18 sorbent cartridges. Other techniques are ultrasonic extraction, heat reflux extraction, microwave-assisted extraction, critical carbon dioxide, high-pressure liquid extraction or use of ethanol in an immersion extractor. The extraction conditions (temperature, extraction time, ratio of solvent to raw material, particle size of the sample, solvent type, and solvent concentrations) for different raw materials and extraction methods have to be optimized. Mainly found in the fruit skins and seeds, high levels of polyphenols may reflect only the measured extractable polyphenol (EPP) content of a fruit which may also contain non-extractable polyphenols. Black tea contains high amounts of polyphenol and makes up for 20% of its weight. Concentration can be made by ultrafiltration. Purification can be achieved by preparative chromatography.
Sources: en.wikipedia.org
The peptide is synthetic, but its sequence matches a segment of a protein present in human gastric juice. It does not occur as a free fifteen-residue peptide in the body.
Rodents account for the large majority of published experiments. Human data are sparse and mostly observational, so cross-species extrapolation remains uncertain.
It is not an approved therapeutic in most jurisdictions. Regulatory status varies by country, and several places restrict it as a research chemical.
The letters BPC stand for body protection compound. The number 157 refers to a specific fragment designation from early work on gastric proteins. The full name is a label for a synthetic fifteen-amino-acid peptide rather than a naturally isolated drug.